Yuan-I Min

Yuan-I Min

Auto-generated profile, based on publicly available information

Yuan-I Min

Department of Medicine, University of Mississippi Medical Center, Jackson, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 1993 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KDKay Dickersin
Kay Dickersin
YMYuan‐I Min
Yuan‐I Min

3 July 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
SYSteve Yadlowsky
Steve Yadlowsky
RHRodney A. Hayward
Rodney A. Hayward
JSJeremy B. Sussman
Jeremy B. Sussman
RMRobyn L. McClelland
Robyn L. McClelland
YMYuan-I Min
Yuan-I Min
SBSanjay Basu
Sanjay Basu
Current guidelines recommend aspirin, statins, and antihypertensive drugs to prevent coronary artery disease in high-risk persons. Deciding whether risk is high enough to warrant these intervention... Background: The 2013 pooled cohort equations (PCEs) are central in prevention guidelines for cardiovascular disease (CVD) but can misestimate CVD risk. Objective: To improve the clinical accuracy o...

28 June 2005 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
PSPhilip Seo
Philip Seo
YMYuan‐I. Min
Yuan‐I. Min
JHJanet T. Holbrook
Janet T. Holbrook
GHGary S. Hoffman
Gary S. Hoffman
PMPeter A. Merkel
Peter A. Merkel
WGWGET Research Group
WGET Research Group
Objective: To analyze damage occurring in patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET) and to correlate that damage with disease activity, adverse events, and quality of life.Methods: The Vasculitis Damage Index (VDI) was applied to all 180 patients at trial entry and every 6 months throughout the trial. Items of damage were analyzed by presumed etiology (i.e., secondary to WG, to therapy, or both) and time of occurrence. Spearman's rank correlation coefficients were calculated between VDI scores and the Birmingham Vasculitis Activity Score for WG (BVAS/WG), frequency of flares, number of adverse events, and the patients' quality‐of‐life assessments.Results: The mean VDI score was 1.3 at the study enrollment and 1.8 at the end of the trial. This increase was due to damage that occurred despite (or because of) therapy, including visual impairment, hearing loss, nasal blockade, pulmonary fibrosis, hypertension, renal insufficiency, peripheral neuropathy, gonadal failure, and diabetes mellitus. Only 11% of the enrolled patients had not sustained a single VDI item after 1 year of enrollment. When adjusted for baseline VDI, the baseline BVAS/WG correlated moderately well with the VDI score at 1 year (r = 0.20, P = 0.015). Increases in adjusted VDI scores also correlated with the number of adverse events, particularly among patients with limited WG (P = 0.06).Conclusion: Damage from both active disease and its treatment remain important problems for patients with WG. Despite the dramatic improvements in patient survival achieved over the last several decades, only a few patients with WG emerge from a period of active disease without sustaining some damage from the disease itself, its treatment, or both. An important measure of future therapeutic approaches will be their ability to reduce the damage accrued over time.

27 April 2006 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
JSJohn H. Stone
John H. Stone
JHJanet T. Holbrook
Janet T. Holbrook
MMMatthew A. Marriott
Matthew A. Marriott
ATAndrea K. Tibbs
Andrea K. Tibbs
LSLourdes P. Sejismundo
Lourdes P. Sejismundo
GHGary S. Hoffman
Gary S. Hoffman

1 December 2019 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
DCDonald Clark
Donald Clark
LCLisandro D. Colantonio
Lisandro D. Colantonio
YMYuan-I Min
Yuan-I Min
MHMichael E. Hall
Michael E. Hall
HZHong Zhao
Hong Zhao
PMPaul Muntner
Paul Muntner
Hypertension is the leading contributor to cardiovascular disease (CVD) in the United States and worldwide; the prevalence of hypertension is higher among black adults compared with other racial/ethnic groups.1 According to an analysis of the 2011-2014 National Health and Nutrition Examination Survey (NHANES),2 54.9% of non-Hispanic black adults in the United States have hypertension as defined by the 2017 American College of Cardiology/American Heart Association (ACC/AHA) blood pressure (BP) guideline (ie, systolic BP [SBP] ≥130 mm Hg, diastolic BP [DBP] ≥80 mm Hg, or antihypertensive medication use). For comparison, 47.3% of non-Hispanic white, 36.7% of non-Hispanic Asian, and 34.4% of Hispanic adults in the United States had hypertension.2

28 April 1993
Verified
Journal Article
Closed access
KDK Dickersin
K Dickersin
YMY I Min
Y I Min